We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

1138:HKEXDgenx Co., Ltd. Analysis

Data as of 2026-05-31 - not real-time

₩600.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Dgenx Co., Ltd. (1138) is trading at KRW 600, well below its DCF‑derived fair value of approximately KRW 1,098, indicating a substantial valuation gap. Technical indicators are bearish: the price sits under the 20‑day (670.75), 50‑day (712.3) and 200‑day (796.3) moving averages, the MACD line (-27.42) is below its signal (-23.32) and the RSI of 29.98 suggests oversold conditions but without clear reversal momentum. Volume is on a decreasing trend and the stock is hovering just above its identified support at KRW 590, with resistance near KRW 738, while volatility remains high at 59% over the past 30 days. Fundamentally, revenue has fallen 25% year‑over‑year, margins are thin (gross 12.1%, operating -6.6%, profit 0.9%), and the company carries a debt‑to‑equity ratio of 65% despite holding KRW 11.46 bn in cash, raising concerns about leverage. The dividend yield of 2.51% appears attractive, yet the payout ratio is effectively zero and earnings per share are nil, questioning sustainability. Market sentiment is extremely bullish (Fear‑Greed Index 94), but the stock’s beta of 0.45 signals limited sensitivity to broader market moves. Overall, the combination of a deep valuation discount, weak operating performance, and heightened short‑term technical pressure suggests caution, while the long‑run upside potential remains tied to a possible turnaround or strategic repositioning.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below all major moving averages
  • Bearish MACD and decreasing volume
  • Proximity to support level with high volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant valuation gap to DCF fair value
  • Strong cash position offset by high debt
  • Uncertain earnings recovery despite dividend yield

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Potential upside if operational turnaround occurs
  • Undervaluation relative to intrinsic value
  • Low beta suggesting limited market‑wide downside exposure

Key Metrics & Analysis

Financial Health

Revenue Growth-24.90%
Profit Margin0.92%
ROE2.47%
ROA0.59%
Debt/Equity65.02
Op. Cash Flow₩3.3B
Free Cash Flow₩3.0B

Technical Analysis

TrendBearish
RSI30.0
Support₩590.00
Resistance₩738.00
MA 20₩670.75
MA 50₩712.30
MA 200₩796.30
MACDBearish
VolumeDecreasing
Fear & Greed Index94.07

Valuation

Fair Value₩1,098.35
GradeUndervalued
TypeValue
Dividend Yield2.51%

Risk Assessment

Beta0.45
Volatility59.35%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.